The P4 Precision Medicine Accelerator, dedicated to supporting the UK’s leading precision medicine startups, recently hosted a demo day for the ten companies from its 2023 cohort to showcase their innovations to an audience of investors and ecosystem supporters.
The event was hosted by Lotus Qi, Head of MedTech at Capital Enterprise, and Dr Phil Beales, Professor of Medical Genetics at University College London, as well as a seasoned innovation leader and co-founder of the P4 Precision Medicine programme.
The companies, selected from over 60 applicants, are developing cutting-edge products across a range of areas, including drug development, immunotherapy, femtech and neuroscience.
Here are the 10 companies who pitched:
In vitro human skin models – Alcyomics is developing in vitro human skin models to accelerate drug development and toxicity testing, reducing reliance on animal testing and improving the speed to market for new drug candidates.
Cancer tumour precision targeting – Bioleap is leveraging proprietary hybrid biophysical/AI computational models to predict the efficacy of complex immunotherapies and identify potential co-target or combination therapies.
Groundbreaking cardiovascular disease discovery – Echopoint Medical is developing non-invasive devices for precision interventions with optical sensing, addressing the challenge of diagnosing and treating chest pain with the iKor platform.
Revolutionary menopause theranostics – Ru medical is focused on developing innovative solutions for menopause, introducing Coolzen, a wearable that detects and mitigates hot flashes through neural pathway stimulation.
Passive neurodegeneration detection – Myndspan is using artificial intelligence and machine learning to analyse brainwave data for improved mental health diagnosis and the development of new treatments for neurological disorders.
AI-powered precision dosing and drug monitoring – ZiO Health has developed proprietary biosensor technology for therapeutic drug monitoring (TDM) and precision dosing, aiming to improve patient drug treatment outcomes with their AI-driven, hand-held point-of-care device.
Improving tumour eradication with real-time simulations – NE Scientific is developing novel surgical guidance tools for oncology, providing real-time simulation technologies to support physicians in targeting tissues during minimally invasive procedures, improving tumour eradication rates and reducing recurrence risks.
Passive neurodegeneration detection – NX10 is predicting and managing brain health by harnessing brain performance data, enabling patients to take control of their life planning and make the most of their time by detecting early signs of cognitive decline and dementia.
Preventative healthcare that empowers employees – Qured is a preventative healthcare platform empowering employees to take control of their health through personalised screening programs, from vital organ function to common cancers and fertility/menopause.
Personalised tinnitus treatment plans – MindEar has developed the Tinnibot app, a companion for tinnitus relief using advanced algorithms and machine learning to provide personalised guidance and adapt to the user’s reaction to tinnitus, making it less noticeable.
Thanks to all the founders for their hard work, and to the investors and ecosystem partners who came out to see them pitch.
This demo day also marks the close of an era for the P4 programme. Starting next year, P4 will stand apart from Capital Enterprise, continuing its work with the medtech ecosystem under the leadership of co-founder Nathan McNally.
We are very proud of everything that P4 has accomplished over the past five years and wish Nathan the best of luck with P4 in the future.